Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2015 · 10-Q
Revenue$349.00K$349.00K— vs Q3 2014 Net Income-$1.68M-$1.68MN/M vs Q3 2014 EPS Diluted-$0.02-$0.02N/M vs Q3 2014 Operating Income-$1,688,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,325,000N/M Margins · derivedOperating margin-483.7%
Net margin-480.5%
ended Mar 31, 2015 · filed May 15, 2015 · 45 d after period end